Theme

Healthcare & Life Sciences

Pharma, biotech, devices, tools and managed care.

87 covered names · ranked by fair value vs price

Dentsply Sirona Inc (XRAY)

BUY. 12-month probability-weighted target $15 (+67% vs spot). Gross Margin explains 66% of Monte Carlo outcome variance.

XRAYEquity ResearchMonte Carlo

10 October 2026Rating: BUY · Fair value vs price +36.1%

Equity Research

Align Technology Inc (ALGN)

BUY. 12-month probability-weighted target $167 (+17% vs spot). P/E Multiple explains 64% of Monte Carlo outcome variance.

ALGNEquity ResearchMonte Carlo

10 October 2026Rating: BUY · Fair value vs price +30.2%

Equity Research

The Cooper Companies, Inc (COO)

BUY. 12-month probability-weighted target $69 (+27% vs spot). P/E Multiple explains 66% of Monte Carlo outcome variance.

COOEquity ResearchMonte Carlo

10 October 2026Rating: BUY · Fair value vs price +24.7%

Equity Research

Neurocrine Biosciences Inc (NBIX)

BUY. 12-month probability-weighted target $170 (+19% vs spot). P/E Multiple explains 81% of Monte Carlo outcome variance.

NBIXEquity ResearchMonte Carlo

10 October 2026Rating: BUY · Fair value vs price +15.9%

Equity Research

DaVita HealthCare Partners Inc (DVA)

BUY. 12-month probability-weighted target $212 (+18% vs spot). Gross Margin explains 60% of Monte Carlo outcome variance.

DVAEquity ResearchMonte Carlo

10 October 2026Rating: BUY · Fair value vs price +13.3%

Equity Research

Jazz Pharmaceuticals PLC (JAZZ)

HOLD. 12-month probability-weighted target $245 (+12% vs spot). P/E Multiple explains 90% of Monte Carlo outcome variance.

JAZZEquity ResearchMonte Carlo

10 October 2026Rating: HOLD · Fair value vs price +8.6%

Equity Research

Centene Corp (CNC)

HOLD. 12-month probability-weighted target $63 (-3% vs spot). Gross Margin explains 81% of Monte Carlo outcome variance.

CNCEquity ResearchMonte Carlo

10 October 2026Rating: HOLD · Fair value vs price +5.6%

Equity Research

Globus Medical (GMED)

HOLD. 12-month probability-weighted target $74 (-1% vs spot). P/E Multiple explains 69% of Monte Carlo outcome variance.

GMEDEquity ResearchMonte Carlo

10 October 2026Rating: HOLD · Fair value vs price +4.2%

Equity Research

HealthEquity Inc (HQY)

HOLD. 12-month probability-weighted target $97 (+5% vs spot). P/E Multiple explains 78% of Monte Carlo outcome variance.

HQYEquity ResearchMonte Carlo

10 October 2026Rating: HOLD · Fair value vs price +0.6%

Equity Research

Envista Holdings Corp (NVST)

HOLD. 12-month probability-weighted target $26 (+12% vs spot). Gross Margin explains 67% of Monte Carlo outcome variance.

NVSTEquity ResearchMonte Carlo

10 October 2026Rating: HOLD · Fair value vs price +0.4%

Equity Research

Cardinal Health Inc (CAH)

HOLD. 12-month probability-weighted target $231 (-3% vs spot). Gross Margin explains 82% of Monte Carlo outcome variance.

CAHEquity ResearchMonte Carlo

10 October 2026Rating: HOLD · Fair value vs price +0.4%

Equity Research

CVS Health Corp (CVS)

BUY. 12-month probability-weighted target $102 (+18% vs spot). Gross Margin explains 66% of Monte Carlo outcome variance.

CVSEquity ResearchMonte Carlo

10 October 2026Rating: BUY · Fair value vs price +0.3%

Equity Research

Stryker Corporation (SYK)

HOLD. 12-month probability-weighted target $309 (+12% vs spot). P/E Multiple explains 69% of Monte Carlo outcome variance.

SYKEquity ResearchMonte Carlo

10 October 2026Rating: HOLD · Fair value vs price +0.2%

Equity Research

LivaNova PLC (LIVN)

HOLD. 12-month probability-weighted target $77 (+1% vs spot). P/E Multiple explains 58% of Monte Carlo outcome variance.

LIVNEquity ResearchMonte Carlo

10 October 2026Rating: HOLD · Fair value vs price -0.5%

Equity Research

Insulet Corporation (PODD)

HOLD. 12-month probability-weighted target $149 (+10% vs spot). P/E Multiple explains 53% of Monte Carlo outcome variance.

PODDEquity ResearchMonte Carlo

10 October 2026Rating: HOLD · Fair value vs price -0.7%

Equity Research

Boston Scientific Corp (BSX)

HOLD. 12-month probability-weighted target $43 (+1% vs spot). P/E Multiple explains 70% of Monte Carlo outcome variance.

BSXEquity ResearchMonte Carlo

10 October 2026Rating: HOLD · Fair value vs price -0.8%

Equity Research

Lantheus Holdings Inc (LNTH)

HOLD. 12-month probability-weighted target $104 (+4% vs spot). P/E Multiple explains 72% of Monte Carlo outcome variance.

LNTHEquity ResearchMonte Carlo

10 October 2026Rating: HOLD · Fair value vs price -1.3%

Equity Research

Zoetis Inc (ZTS)

HOLD. 12-month probability-weighted target $74 (-1% vs spot). P/E Multiple explains 76% of Monte Carlo outcome variance.

ZTSEquity ResearchMonte Carlo

10 October 2026Rating: HOLD · Fair value vs price -1.7%

Equity Research

UnitedHealth Group Incorporated (UNH)

HOLD. 12-month probability-weighted target $394 (+4% vs spot). Gross Margin explains 67% of Monte Carlo outcome variance.

UNHEquity ResearchMonte Carlo

10 October 2026Rating: HOLD · Fair value vs price -2.7%

Equity Research

Biomarin Pharmaceutical Inc (BMRN)

HOLD. 12-month probability-weighted target $58 (+6% vs spot). P/E Multiple explains 77% of Monte Carlo outcome variance.

BMRNEquity ResearchMonte Carlo

10 October 2026Rating: HOLD · Fair value vs price -3.5%

Equity Research

Viatris Inc (VTRS)

HOLD. 12-month probability-weighted target $20 (+11% vs spot). P/E Multiple explains 65% of Monte Carlo outcome variance.

VTRSEquity ResearchMonte Carlo

10 October 2026Rating: HOLD · Fair value vs price -4.6%

Equity Research

Edwards Lifesciences Corp (EW)

HOLD. 12-month probability-weighted target $86 (+1% vs spot). P/E Multiple explains 76% of Monte Carlo outcome variance.

EWEquity ResearchMonte Carlo

10 October 2026Rating: HOLD · Fair value vs price -4.6%

Equity Research

Cigna Corp (CI)

HOLD. 12-month probability-weighted target $269 (-5% vs spot). Gross Margin explains 67% of Monte Carlo outcome variance.

CIEquity ResearchMonte Carlo

10 October 2026Rating: HOLD · Fair value vs price -5.2%

Equity Research

Exelixis Inc (EXEL)

HOLD. 12-month probability-weighted target $56 (-6% vs spot). P/E Multiple explains 93% of Monte Carlo outcome variance.

EXELEquity ResearchMonte Carlo

10 October 2026Rating: HOLD · Fair value vs price -5.5%

Equity Research

Cencora Inc. (COR)

SELL. 12-month probability-weighted target $279 (-14% vs spot). Gross Margin explains 82% of Monte Carlo outcome variance.

COREquity ResearchMonte Carlo

10 October 2026Rating: SELL · Fair value vs price -8.2%

Equity Research

STERIS plc (STE)

HOLD. 12-month probability-weighted target $207 (-4% vs spot). P/E Multiple explains 60% of Monte Carlo outcome variance.

STEEquity ResearchMonte Carlo

10 October 2026Rating: HOLD · Fair value vs price -8.4%

Equity Research

IDEXX Laboratories Inc (IDXX)

HOLD. 12-month probability-weighted target $534 (+3% vs spot). P/E Multiple explains 75% of Monte Carlo outcome variance.

IDXXEquity ResearchMonte Carlo

10 October 2026Rating: HOLD · Fair value vs price -9.2%

Equity Research

Chemed Corp (CHE)

HOLD. 12-month probability-weighted target $502 (+1% vs spot). Gross Margin explains 48% of Monte Carlo outcome variance.

CHEEquity ResearchMonte Carlo

10 October 2026Rating: HOLD · Fair value vs price -9.4%

Equity Research

United Therapeutics Corporation (UTHR)

HOLD. 12-month probability-weighted target $513 (-7% vs spot). P/E Multiple explains 86% of Monte Carlo outcome variance.

UTHREquity ResearchMonte Carlo

10 October 2026Rating: HOLD · Fair value vs price -9.9%

Equity Research

Bristol-Myers Squibb Company (BMY)

HOLD. 12-month probability-weighted target $56 (-6% vs spot). P/E Multiple explains 77% of Monte Carlo outcome variance.

BMYEquity ResearchMonte Carlo

10 October 2026Rating: HOLD · Fair value vs price -10.0%

Equity Research

Medtronic PLC (MDT)

HOLD. 12-month probability-weighted target $85 (-4% vs spot). P/E Multiple explains 66% of Monte Carlo outcome variance.

MDTEquity ResearchMonte Carlo

10 October 2026Rating: HOLD · Fair value vs price -11.0%

Equity Research

ResMed Inc (RMD)

SELL. 12-month probability-weighted target $198 (-14% vs spot). P/E Multiple explains 80% of Monte Carlo outcome variance.

RMDEquity ResearchMonte Carlo

10 October 2026Rating: SELL · Fair value vs price -12.7%

Equity Research

Regeneron Pharmaceuticals Inc (REGN)

SELL. 12-month probability-weighted target $605 (-19% vs spot). P/E Multiple explains 84% of Monte Carlo outcome variance.

REGNEquity ResearchMonte Carlo

10 October 2026Rating: SELL · Fair value vs price -12.9%

Equity Research

GE HealthCare Technologies Inc. (GEHC)

HOLD. 12-month probability-weighted target $62 (-5% vs spot). Gross Margin explains 60% of Monte Carlo outcome variance.

GEHCEquity ResearchMonte Carlo

10 October 2026Rating: HOLD · Fair value vs price -13.1%

Equity Research

Zimmer Biomet Holdings Inc (ZBH)

HOLD. 12-month probability-weighted target $89 (+0% vs spot). P/E Multiple explains 63% of Monte Carlo outcome variance.

ZBHEquity ResearchMonte Carlo

10 October 2026Rating: HOLD · Fair value vs price -13.3%

Equity Research

Abbott Laboratories (ABT)

HOLD. 12-month probability-weighted target $92 (-8% vs spot). P/E Multiple explains 67% of Monte Carlo outcome variance.

ABTEquity ResearchMonte Carlo

10 October 2026Rating: HOLD · Fair value vs price -15.4%

Equity Research

Henry Schein Inc (HSIC)

HOLD. 12-month probability-weighted target $83 (-2% vs spot). Gross Margin explains 69% of Monte Carlo outcome variance.

HSICEquity ResearchMonte Carlo

10 October 2026Rating: HOLD · Fair value vs price -15.6%

Equity Research

Medpace Holdings Inc (MEDP)

SELL. 12-month probability-weighted target $523 (-15% vs spot). P/E Multiple explains 66% of Monte Carlo outcome variance.

MEDPEquity ResearchMonte Carlo

10 October 2026Rating: SELL · Fair value vs price -16.2%

Equity Research

Elanco Animal Health (ELAN)

HOLD. 12-month probability-weighted target $25 (+7% vs spot). Gross Margin explains 51% of Monte Carlo outcome variance.

ELANEquity ResearchMonte Carlo

10 October 2026Rating: HOLD · Fair value vs price -17.1%

Equity Research

Intuitive Surgical Inc (ISRG)

HOLD. 12-month probability-weighted target $397 (-6% vs spot). P/E Multiple explains 83% of Monte Carlo outcome variance.

ISRGEquity ResearchMonte Carlo

10 October 2026Rating: HOLD · Fair value vs price -17.6%

Equity Research

Biogen Inc (BIIB)

SELL. 12-month probability-weighted target $191 (-15% vs spot). P/E Multiple explains 64% of Monte Carlo outcome variance.

BIIBEquity ResearchMonte Carlo

10 October 2026Rating: SELL · Fair value vs price -17.9%

Equity Research

Vertex Pharmaceuticals Inc (VRTX)

SELL. 12-month probability-weighted target $457 (-10% vs spot). P/E Multiple explains 82% of Monte Carlo outcome variance.

VRTXEquity ResearchMonte Carlo

10 October 2026Rating: SELL · Fair value vs price -18.0%

Equity Research

Elevance Health Inc (ELV)

HOLD. 12-month probability-weighted target $371 (-10% vs spot). Gross Margin explains 67% of Monte Carlo outcome variance.

ELVEquity ResearchMonte Carlo

10 October 2026Rating: HOLD · Fair value vs price -18.3%

Equity Research

Johnson & Johnson (JNJ)

HOLD. 12-month probability-weighted target $236 (-10% vs spot). P/E Multiple explains 77% of Monte Carlo outcome variance.

JNJEquity ResearchMonte Carlo

10 October 2026Rating: HOLD · Fair value vs price -18.7%

Equity Research

McKesson Corporation (MCK)

SELL. 12-month probability-weighted target $770 (-18% vs spot). Gross Margin explains 80% of Monte Carlo outcome variance.

MCKEquity ResearchMonte Carlo

10 October 2026Rating: SELL · Fair value vs price -19.1%

Equity Research

Danaher Corporation (DHR)

SELL. 12-month probability-weighted target $191 (-13% vs spot). P/E Multiple explains 73% of Monte Carlo outcome variance.

DHREquity ResearchMonte Carlo

10 October 2026Rating: SELL · Fair value vs price -19.4%

Equity Research

Eli Lilly and Company (LLY)

HOLD. 12-month probability-weighted target $1084 (-8% vs spot). P/E Multiple explains 86% of Monte Carlo outcome variance.

LLYEquity ResearchMonte Carlo

10 October 2026Rating: HOLD · Fair value vs price -19.8%

Equity Research

West Pharmaceutical Services Inc (WST)

HOLD. 12-month probability-weighted target $338 (-8% vs spot). P/E Multiple explains 64% of Monte Carlo outcome variance.

WSTEquity ResearchMonte Carlo

10 October 2026Rating: HOLD · Fair value vs price -20.6%

Equity Research

HCA Healthcare, Inc. (HCA)

SELL. 12-month probability-weighted target $392 (-13% vs spot). Gross Margin explains 61% of Monte Carlo outcome variance.

HCAEquity ResearchMonte Carlo

10 October 2026Rating: SELL · Fair value vs price -21.3%

Equity Research

Sotera Health Co (SHC)

HOLD. 12-month probability-weighted target $17 (-3% vs spot). P/E Multiple explains 70% of Monte Carlo outcome variance.

SHCEquity ResearchMonte Carlo

10 October 2026Rating: HOLD · Fair value vs price -22.8%

Equity Research

Bruker Corporation (BRKR)

HOLD. 12-month probability-weighted target $54 (-8% vs spot). Gross Margin explains 64% of Monte Carlo outcome variance.

BRKREquity ResearchMonte Carlo

10 October 2026Rating: HOLD · Fair value vs price -23.2%

Equity Research

Bio-Rad Laboratories Inc (BIO)

SELL. 12-month probability-weighted target $299 (-18% vs spot). Gross Margin explains 60% of Monte Carlo outcome variance.

BIOEquity ResearchMonte Carlo

10 October 2026Rating: SELL · Fair value vs price -23.4%

Equity Research

Gilead Sciences Inc (GILD)

SELL. 12-month probability-weighted target $120 (-21% vs spot). P/E Multiple explains 81% of Monte Carlo outcome variance.

GILDEquity ResearchMonte Carlo

10 October 2026Rating: SELL · Fair value vs price -23.5%

Equity Research

Pfizer Inc (PFE)

SELL. 12-month probability-weighted target $23 (-19% vs spot). P/E Multiple explains 75% of Monte Carlo outcome variance.

PFEEquity ResearchMonte Carlo

10 October 2026Rating: SELL · Fair value vs price -23.6%

Equity Research

AbbVie Inc (ABBV)

SELL. 12-month probability-weighted target $232 (-16% vs spot). P/E Multiple explains 82% of Monte Carlo outcome variance.

ABBVEquity ResearchMonte Carlo

10 October 2026Rating: SELL · Fair value vs price -25.5%

Equity Research

Agilent Technologies Inc (A)

SELL. 12-month probability-weighted target $131 (-23% vs spot). P/E Multiple explains 73% of Monte Carlo outcome variance.

AEquity ResearchMonte Carlo

10 October 2026Rating: SELL · Fair value vs price -25.5%

Equity Research

Waters Corporation (WAT)

SELL. 12-month probability-weighted target $359 (-17% vs spot). P/E Multiple explains 82% of Monte Carlo outcome variance.

WATEquity ResearchMonte Carlo

10 October 2026Rating: SELL · Fair value vs price -25.6%

Equity Research

DexCom Inc (DXCM)

SELL. 12-month probability-weighted target $65 (-23% vs spot). P/E Multiple explains 67% of Monte Carlo outcome variance.

DXCMEquity ResearchMonte Carlo

10 October 2026Rating: SELL · Fair value vs price -26.2%

Equity Research

Amgen Inc (AMGN)

SELL. 12-month probability-weighted target $350 (-16% vs spot). P/E Multiple explains 80% of Monte Carlo outcome variance.

AMGNEquity ResearchMonte Carlo

10 October 2026Rating: SELL · Fair value vs price -26.2%

Equity Research

Laboratory Corporation of America Holdings (LH)

SELL. 12-month probability-weighted target $277 (-11% vs spot). Gross Margin explains 58% of Monte Carlo outcome variance.

LHEquity ResearchMonte Carlo

10 October 2026Rating: SELL · Fair value vs price -27.2%

Equity Research

Mettler-Toledo International Inc (MTD)

SELL. 12-month probability-weighted target $1228 (-21% vs spot). P/E Multiple explains 72% of Monte Carlo outcome variance.

MTDEquity ResearchMonte Carlo

10 October 2026Rating: SELL · Fair value vs price -28.8%

Equity Research

Merck & Company Inc (MRK)

SELL. 12-month probability-weighted target $120 (-17% vs spot). P/E Multiple explains 65% of Monte Carlo outcome variance.

MRKEquity ResearchMonte Carlo

10 October 2026Rating: SELL · Fair value vs price -30.6%

Equity Research

Repligen Corporation (RGEN)

SELL. 12-month probability-weighted target $125 (-28% vs spot). P/E Multiple explains 76% of Monte Carlo outcome variance.

RGENEquity ResearchMonte Carlo

10 October 2026Rating: SELL · Fair value vs price -31.1%

Equity Research

Quest Diagnostics Incorporated (DGX)

SELL. 12-month probability-weighted target $201 (-13% vs spot). Gross Margin explains 55% of Monte Carlo outcome variance.

DGXEquity ResearchMonte Carlo

10 October 2026Rating: SELL · Fair value vs price -31.3%

Equity Research

Thermo Fisher Scientific Inc (TMO)

SELL. 12-month probability-weighted target $505 (-23% vs spot). P/E Multiple explains 67% of Monte Carlo outcome variance.

TMOEquity ResearchMonte Carlo

10 October 2026Rating: SELL · Fair value vs price -31.5%

Equity Research

Baxter International Inc (BAX)

SELL. 12-month probability-weighted target $20 (-18% vs spot). Gross Margin explains 66% of Monte Carlo outcome variance.

BAXEquity ResearchMonte Carlo

10 October 2026Rating: SELL · Fair value vs price -31.7%

Equity Research

Becton Dickinson and Company (BDX)

SELL. 12-month probability-weighted target $144 (-21% vs spot). P/E Multiple explains 56% of Monte Carlo outcome variance.

BDXEquity ResearchMonte Carlo

10 October 2026Rating: SELL · Fair value vs price -33.6%

Equity Research

Halozyme Therapeutics Inc (HALO)

SELL. 12-month probability-weighted target $77 (-30% vs spot). P/E Multiple explains 87% of Monte Carlo outcome variance.

HALOEquity ResearchMonte Carlo

10 October 2026Rating: SELL · Fair value vs price -34.8%

Equity Research

Universal Health Services Inc (UHS)

SELL. 12-month probability-weighted target $138 (-22% vs spot). Gross Margin explains 64% of Monte Carlo outcome variance.

UHSEquity ResearchMonte Carlo

10 October 2026Rating: SELL · Fair value vs price -35.9%

Equity Research

Encompass Health Corp (EHC)

SELL. 12-month probability-weighted target $96 (-22% vs spot). Gross Margin explains 56% of Monte Carlo outcome variance.

EHCEquity ResearchMonte Carlo

10 October 2026Rating: SELL · Fair value vs price -36.2%

Equity Research

Revvity Inc. (RVTY)

SELL. 12-month probability-weighted target $107 (-31% vs spot). P/E Multiple explains 65% of Monte Carlo outcome variance.

RVTYEquity ResearchMonte Carlo

10 October 2026Rating: SELL · Fair value vs price -37.7%

Equity Research

Haemonetics Corporation (HAE)

SELL. 12-month probability-weighted target $78 (-34% vs spot). P/E Multiple explains 59% of Monte Carlo outcome variance.

HAEEquity ResearchMonte Carlo

10 October 2026Rating: SELL · Fair value vs price -38.7%

Equity Research

Charles River Laboratories (CRL)

SELL. 12-month probability-weighted target $206 (-32% vs spot). P/E Multiple explains 50% of Monte Carlo outcome variance.

CRLEquity ResearchMonte Carlo

10 October 2026Rating: SELL · Fair value vs price -38.7%

Equity Research

Option Care Health Inc (OPCH)

SELL. 12-month probability-weighted target $22 (-28% vs spot). Gross Margin explains 64% of Monte Carlo outcome variance.

OPCHEquity ResearchMonte Carlo

10 October 2026Rating: SELL · Fair value vs price -39.4%

Equity Research

The Ensign Group Inc (ENSG)

SELL. 12-month probability-weighted target $123 (-28% vs spot). Gross Margin explains 63% of Monte Carlo outcome variance.

ENSGEquity ResearchMonte Carlo

10 October 2026Rating: SELL · Fair value vs price -40.6%

Equity Research

IQVIA Holdings Inc (IQV)

SELL. 12-month probability-weighted target $186 (-28% vs spot). P/E Multiple explains 49% of Monte Carlo outcome variance.

IQVEquity ResearchMonte Carlo

10 October 2026Rating: SELL · Fair value vs price -40.9%

Equity Research

Illumina Inc (ILMN)

SELL. 12-month probability-weighted target $179 (-36% vs spot). P/E Multiple explains 65% of Monte Carlo outcome variance.

ILMNEquity ResearchMonte Carlo

10 October 2026Rating: SELL · Fair value vs price -41.7%

Equity Research

Tenet Healthcare Corporation (THC)

SELL. 12-month probability-weighted target $188 (-29% vs spot). Gross Margin explains 62% of Monte Carlo outcome variance.

THCEquity ResearchMonte Carlo

10 October 2026Rating: SELL · Fair value vs price -43.7%

Equity Research

Humana Inc (HUM)

SELL. 12-month probability-weighted target $219 (-49% vs spot). Gross Margin explains 89% of Monte Carlo outcome variance.

HUMEquity ResearchMonte Carlo

10 October 2026Rating: SELL · Fair value vs price -45.5%

Equity Research

Avantor Inc (AVTR)

SELL. 12-month probability-weighted target $10 (-34% vs spot). Gross Margin explains 63% of Monte Carlo outcome variance.

AVTREquity ResearchMonte Carlo

10 October 2026Rating: SELL · Fair value vs price -47.4%

Equity Research

Penumbra Inc (PEN)

Rating suspended since 2026-09-29 — valuation method under review. The rating, price target and expected return are withheld until the name is re-valued; the research on the report page predates the review.

PENEquity ResearchMonte Carlo

10 October 2026Rating: N/A

Equity Research

Incyte Corporation (INCY)

Rating suspended since 2026-09-21 — valuation input under review. The rating, price target and expected return are withheld until the name is re-valued; the research on the report page predates the review.

INCYEquity ResearchMonte Carlo

10 October 2026Rating: N/A

Equity Research

Hims Hers Health Inc (HIMS)

Rating suspended since 2026-09-29 — valuation input under review. The rating, price target and expected return are withheld until the name is re-valued; the research on the report page predates the review.

HIMSEquity ResearchMonte Carlo

10 October 2026Rating: N/A

Equity Research

BrightSpring Health Services, Inc. Common Stock (BTSG)

BTSGEquity ResearchMonte Carlo

10 October 2026Rating: N/A

Equity Research

Arrowhead Pharmaceuticals Inc (ARWR)

ARWREquity ResearchMonte Carlo

10 October 2026Rating: N/A

Equity Research

Cytokinetics Inc (CYTK)

Rating suspended since 2026-10-03 — valuation method under review. The rating, price target and expected return are withheld until the name is re-valued; the research on the report page predates the review.

CYTKEquity ResearchMonte Carlo

11 September 2026Rating: N/A

Equity Research

Bio-Techne Corp (TECH)

Rating suspended since 2026-10-10 — pending acquisition. The rating, price target and expected return are withheld until the name is re-valued; the research on the report page predates the review.

TECHEquity ResearchMonte Carlo

30 July 2026Rating: N/A